Plasma Cell DNA Content and Proliferation, Bone Marrow
Use
This test is useful for establishing a diagnosis of plasma cell proliferative disorders, including multiple myeloma and other related conditions. It provides prognostic information for newly diagnosed multiple myeloma, assesses the response to therapy, and detects disease relapse and progression in treated patients. It determines the plasma cell DNA content and proliferation to provide valuable insights into the disease's clinical progression and aggressiveness.
Special Instructions
This test is always accompanied by flow cytometry interpretation at an additional charge. If reflex FISH testing is needed, order MSMRT / Mayo Algorithmic Approach for Stratification of Myeloma and Risk-Adapted Therapy Report, Bone Marrow. For follow-up, the MSMRD / Myeloma Stratification and Risk-Adapted Therapy with Reflex to Measurable/Minimal Residual Disease, Bone Marrow test may be considered.
Limitations
Plasma cell proliferation may not be determined if fewer than 300 abnormal plasma cell events or when multiple aneuploid cell populations are present. Additionally, the test results rely on accurate specimen processing, and the aging of the specimen could affect the antigen loss, affecting the percentage of clonal plasma cells.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 93363-0
- 93362-2
- 93021-4
- 93361-4
- 93360-6
- 93359-8
- 93358-0
- 93020-6
- 50398-7
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
4 mL
Minimum Volume
2 mL
Container
Yellow top (ACD solution A or B)
Collection Instructions
Ensure marrow specimen is from a 'redirect' aspirate. Acceptable alternative: Lavender top (EDTA) or green top (sodium heparin).
Causes for Rejection
Gross hemolysis, fully clotted specimens will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 3 days |